Trending...
- Suburban Orthopaedics Expands Spine Team with Board-Certified Surgeon Joseph Brindise, DO
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- Digi 995: Warbot Run Officially Launches on the Apple App Store
* HMBD ~ Hummingbird Bioscience, a data-driven precision biotherapeutics company, announced a Trials in Progress poster presentation for HMBD-002, a unique anti-VISTA antibody, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The poster will summarize the Phase 1 clinical trial design for HMBD-002.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
- Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
- LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
- Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- Children Rising Appoints Marshelle A. Wilburn as New Executive Director
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
Filed Under: Business
0 Comments
Latest on illi News
- Tickeron Unveils AI-Powered Trading Insights Aligned with Key Monthly Consumer Data
- 360Massage Launches Custom-Built Massage Chairs Designed to Match Modern Homes
- The Nature of Miracles Celebrates 20th Anniversary Third Edition Published by DreamMakers Enterprises LLC
- City of Naperville Launches New and Improved eBill Portal
- Artificial Intelligence Leader Releases Children's Book on Veterans Day
- Felicia Allen Hits #1 Posthumously with "Christmas Means Worship"
- CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
- Holiday Pond Lighting Ideas for Chicago-Area Water Features
- Tokenized Real-World Assets: Iguabit Brings Institutional Investment Opportunities to Brazil
- MEX Finance meluncurkan platform keuangan berbasis riset yang berfokus pada data, logika, dan efisiensi pengambilan keputusan investasi
- From MelaMed Wellness to Calmly Rooted: A New Chapter in Functional Wellness
- New Angles US Group Founder Alexander Harrington Receives Top U.S. Corporate Training Honor and Leads Asia-Pacific Engagements in Taiwan
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- UK Financial Ltd Sets Official 30-Day Conversion Deadline for Three Exchange Listed Tokens Ahead of Regulated Upgrade
- New Jersey Therapy and Life Coaching Unveils Original Dan Fenelon Mural in Voorhees New Jersey Therapy Office
- Illinois 45th District Candidate Josh Atkinson Introduces a New Way to Reach Voters
- Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
- Suburban Orthopaedics Expands Spine Team with Board-Certified Surgeon Joseph Brindise, DO
- Naperville: Drive Sober or Get Pulled Over This Season